Lexeo Therapeutics, Inc. (LXEO) AI Dilution Summary

Estimated cash was $223,493,481 as of 2026-09-29, from $234,171,000 at 2026-06-30 against estimated monthly burn of $6,456,833, after a $5,300,000 Mantle merger payment on 2026-09-29. The company funds itself through an ATM program with Leerink Partners LLC, authorised to $75,000,000, with $39,612,779.80 sold to date. ATM sales through 2026-07-31 raised $14,100,000 net from 3,109,103 shares.